Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomised, Double-blind, 3-Part Study in Healthy Young and Elderly Subjects to Assess the Safety and Tolerability, and Investigate the Pharmacokinetics of Aztreonam and Avibactam Given Alone and in Combination (ATM-AVI)

Trial Profile

A Phase I, Randomised, Double-blind, 3-Part Study in Healthy Young and Elderly Subjects to Assess the Safety and Tolerability, and Investigate the Pharmacokinetics of Aztreonam and Avibactam Given Alone and in Combination (ATM-AVI)

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2019

At a glance

  • Drugs Avibactam (Primary) ; Avibactam/aztreonam (Primary) ; Aztreonam (Primary)
  • Indications Gram-negative infections; Intra-abdominal infections
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 Apr 2019 Results assessing pharmacokinetic-pharmacodynamic modelling from this study, presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases.
    • 27 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Sep 2014 Planned end date changed from 1 Jun 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top